Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

e commercially available product. The safety data generated to date has shown UDB to be well tolerated with no significant adverse events reported.

MAP0004 Phase 3 Program

MAP Pharmaceuticals expects to complete enrollment in its initial Phase 3 clinical trial for the acute treatment of migraine by the end of January 2009. The Phase 3 multi-center, randomized, double-blind, placebo controlled trial in approximately 850 migraine sufferers is evaluating MAP0004 as a potential acute treatment for migraine. Patients enrolled in the trial will be evaluated for the treatment of a single migraine and will continue to be followed in a long-term safety trial. MAP Pharmaceuticals is conducting this first Phase 3 trial and the long-term safety trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, orally inhaled migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraine for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy- to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes with sustained relief to 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product cand
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... that will expand its current Salt Lake City manufacturing ... underway outside of Utah to ultimately create 1,000 new ... 20 years. , “Utah is home to hardworking ... whom can be credited with Varian’s success in the ...
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... of nature,s mysteries is how plants survive impact ... the sun,s rays, while using this energy for ... in the plant,s blades quickly dissipate the energy ... quakes. Researchers at DTU Physics have now managed ... algae and bacteria contain light-absorbing proteins which play ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2
... catalysts and video displays are among the potential applications ... These particles are named after the two-faced Roman god ... form novel structures and new materials. However, as scientists ... a few nanometers in diameter about the size ...
... Pa., Sept. 27, 2011 Renmatix , ... the Plantrose™ process, the company,s commercial approach to ... to non-food derived low-cost industrial sugars, the foundation ... dramatic shift from petroleum-based fuels and chemicals to ...
... be coming to a little screen near you. These ... of displaying information on cell phones, e-readers and iPads, and ... solar cells, according to new research. Duke chemist Ben ... organize copper atoms in water to form long, thin, non-clumped ...
Cached Biology Technology:New technique maps twin faces of smallest Janus nanoparticles 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 3Copper film could lower touch screen, led and solar cell costs 2
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
(Date:8/28/2014)... than 25 million kilometres of new roads will be ... slice into Earth,s last wildernesses, where they bring an ... , Now, an ambitious study has created a ,global ... try to balance the competing demands of development and ... ,environmental-values, layer that estimates that natural importance of ecosystems ...
(Date:8/28/2014)... areas conserve biodiversity and more action is needed to ... researchers say. , Published in PLOS ONE , ... of Exeter, used meta-analysis - combining results from different ... of research into these areas, to determine whether they ... of Biological Sciences, said protecting an area from human ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Protected areas proven to protect biodiversity 2
... you are a rice breeder and one day within a ... characteristics you have been looking for. You happily take your ... the spontaneous, beneficial event was due to inactivation of a ... many different strains grown in different parts of the world, ...
... biometric products and expanded markets, JERICHO, N.Y., ... and Oki Semiconductor Company, a division of Oki,America ... Industry Co, Ltd.,jointly announced that they are working ... significantly lowering bioMETRX,s overall build costs for,its expanding ...
... The song of passerine birds is a conspicuous and ... of male-male competition or mate attraction. At the level ... male quality. Paola Laiolo and colleagues at ... system of the Duponts lark in north-eastern Spain and ...
Cached Biology News:Less can be more, for plant breeders too 2Less can be more, for plant breeders too 3bioMETRX Incorporates OKI's Fingerprint Engine in its smartTOUCH Product Line 2bioMETRX Incorporates OKI's Fingerprint Engine in its smartTOUCH Product Line 3
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
QPRT Antibody...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
Agarose, Biotechnology grade, 500g...
Biology Products: